EUVIMEDEUVIMED entdecken
Crossref

Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections

Walaiporn Wangchinda, Jason M Pogue iD, Visanu Thamlikitkul iD, Pannee Leelawattanachai, Pornpan Koomanachai, Manjunath P Pai iD

Journal of Antimicrobial Chemotherapy · 03.06.2024 · 79 (6) · 1372-1379

DOI: 10.1093/jac/dkae111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 10.04.2024. Verfasst von Walaiporn Wangchinda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI 48108, USA. Hauptthemen laut MEDLINE: Fosfomycin, Anti-Bacterial Agents, Microbial Sensitivity Tests, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Mahidol University, University of Michigan College of Pharmacy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

IV fosfomycin is used against MDR Gram-negative bacilli (GNB) but has dose-limiting side effects, especially in patients with impaired kidney function.

Objectives

To determine the optimal dosage of IV fosfomycin for patients with varying degrees of kidney function.

Methods

Adult patients receiving IV fosfomycin for treatment of GNB were eligible. Five serial blood samples were collected after at least three doses of fosfomycin; plasma was assayed by LC-MS/MS and modelled by population pharmacokinetic analysis. The PTA for AUC24/MIC of 98.9 for Escherichia coli and Klebsiella pneumoniae, and 40.8 for Pseudomonas aeruginosa were computed by Monte Carlo simulations. Cumulative fractions of response (CFR) were analysed for each pathogen using EUCAST MIC distributions.

Results

A total of 24 patients were included. Creatinine clearance (CLCR) and gender significantly influenced fosfomycin clearance. The kidney function-adjusted dosing regimens are proposed by using the lowest dose that can achieve ≥90% PTA for AUC24/MIC of 98.9 at an MIC of ≤32 mg/L (EUCAST v.13 susceptibility breakpoint for Enterobacterales). For patients with normal kidney function (CLCR 91–120 mL/min), a dosage of 15 g/day is suggested. This regimen achieved 97.1% CFR against E. coli, whereas CFR was 72.9% for K. pneumoniae and 76.7% for P. aeruginosa.

Conclusions

A fosfomycin dosage of 15 g/day with adjustment according to kidney function provided high PTA and CFR when treating E. coli. This dosage is lower than that used in current practice and may improve tolerability. Higher dosages may be needed for P. aeruginosa; however, safety data are limited.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FosfomycinAnti-Bacterial AgentsMicrobial Sensitivity TestsGram-Negative Bacterial InfectionsDrug Resistance, Multiple, BacterialKlebsiella pneumoniaePseudomonas aeruginosaHumansFemaleMaleMiddle AgedAgedAdultEscherichia coliAged, 80 and overAdministration, IntravenousMonte Carlo MethodTandem Mass SpectrometryGram-Negative Bacteria

Substanzen

FosfomycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI 48108, USA.
  • Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Pharmacy, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.

ORCID-Profile: Jason M Pogue, Visanu Thamlikitkul, Manjunath P Pai

Förderung

  • Mahidol University
  • University of Michigan College of Pharmacy

Zitieren

APA

Wangchinda, W., Pogue, J. M., Thamlikitkul, V., Leelawattanachai, P., Koomanachai, P., & Pai, M. P. (2024). Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections. Journal of Antimicrobial Chemotherapy, 79(6), 1372-1379. https://doi.org/10.1093/jac/dkae111

Vancouver

Wangchinda W, Pogue JM, Thamlikitkul V, Leelawattanachai P, Koomanachai P, Pai MP. Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections. Journal of Antimicrobial Chemotherapy. 2024;79(6):1372-1379. doi:10.1093/jac/dkae111

BibTeX
@article{Wangchinda2024,
  author = {Wangchinda, Walaiporn and Pogue, Jason M and Thamlikitkul, Visanu and Leelawattanachai, Pannee and Koomanachai, Pornpan and Pai, Manjunath P},
  title = {Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {6},
  pages = {1372--1379},
  doi = {10.1093/jac/dkae111}
}
Kostenlos starten →